Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with expertise focusing on oral dosage forms for the Pharmaceutical industry. Our specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. We have developed and manufacture more than 45 products sold by customers worldwide.
We have the expertise and proven track record to guide projects from clinical research stages through optimization, validation, and approval. We operate seven facilities in the US and Europe, equipped to facilitate efficient drug product development and manufacturing, maintaining excellent environmental conditions compliant with US and EU cGMP regulations.
Adare has dedicated, engineered high potent GMP manufacturing and development areas. Our in-house regulatory and quality teams have a proven global track record, assuring our clients that products we manufacture are provided with the highest relevant standards for patient care.
Adare Pharma Solutions has four sites located in the US and Europe with over 600 employees worldwide. We have the expertise to take your project from formulation development through commercial scale manufacturing. Our sites are compliant with cGMP criteria and approved to handle controlled substances and maintain excellent environmental credentials. Our in house regulatory and quality teams have a proven global track record with the FDA, AIFA in Italy, EMA in Europe, ANVISA for Brazil and PMDA for Japan.
ADARE’S SPECIALIZED TECHNOLOGIES INCLUDE:
The Parvulet® Technology is a patient-centric dosage solution that enables a solid powder or tablet to convert to a semi-solid in the presence of water within 30 seconds. The final dosage is easily administered as a soft food like texture, which is ideal for pediatric and geriatric populations (including those with dysphagia).
Microcaps® Taste Masking Technology achieves uniform and efficient coating of drug particles by a combination of coacervation (phase separation) and spray coating to build polymeric membranes of varying porosity and thickness. The Microcaps technology can be applied to multiple dosage forms and immediate- and modified-release profiles.
AdvaTab® Orally Disintegrating Tablets (ODTs) incorporates coated or uncoated drug particles that are uniformly dispersed in a low-moisture, rapidly disintegrating matrix. Each ODT is formulated to achieve an acceptable taste and desired release profile. This technology can be combined with Microcaps® and Diffucaps® to create IR or controlled release ODTs.
Diffucaps® Customized Release Technology has the flexibility to incorporate functional, release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals. Beads can have different release profiles, different active ingredients, or both — all in one product.
MMTSTM Multi Mini Tablet System Customized Release Technology combines the simplicity of a tablet formulation with the flexibility of multiparticulate dosage forms with high drug-loading capability. Adare has developed Ultra Microtablets — a smaller standard of tablets targeting diameters in the range of 1.2 mm to even 1.0 mm. The small size facilitates the development of products that can offer multiple drugs or varying release profiles within a single capsule.
The DIFFUTAB® Technology is an effective solution for targeted drug delivery through customized and sustained release. The technology assists the development of high-dosage and sustained-release products for once-daily administration. A matrix tablet is coated with functional polymers, followed by a blend of hydrophilic and hydrophobic polymers. Layered erosion and diffusion of the drug matrix tablet result in a controllable release.
Precision Particle Fabrication® Technology produces uniform microspheres and microcapsules with narrow size distribution and precise control over particle structure. The platform technology is flexible and customizable to accommodate a broad range of active ingredients, including small molecules, peptides, and proteins. The technology includes three platforms: Optimμm®, for oral delivery; StratμmTM, for injectable delivery; and Unisun®, for otic delivery.
Our Commercial Manufacturing Capabilities include:
Granulation and mixing
Fluid bed processing
Blending (Bin and Static)
Microencapsulation of solids and liquids
Orally disintegrating tablet (ODT)
Controlled substances: Manufacturing registration authorized for classes II-V, Analytical Labs authorized for I-V
Posted Date: 12/1/2021
This record has been viewed 4092 times.